The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer

被引:8
|
作者
Konishi, Kenta [1 ]
Ishiba, Ryo [1 ]
Ikenohira, Tsutomu [1 ]
Asao, Tomoyuki [1 ]
Hirata, Masanori [1 ]
Ohira, Keiichi [1 ]
Komatsu, Tetsuya [1 ]
Sawada, Michifumi [2 ]
Tanahashi, Yukichi [3 ]
Goshima, Satoshi [3 ]
Magata, Yasuhiro [4 ]
Nakamura, Katsumasa [1 ]
机构
[1] Hamamatsu Univ Sch Med, Dept Radiat Oncol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[2] Hamamatsu Univ Sch Med, Dept Radiol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Univ Sch Med, Dept Diagnost Radiol & Nucl Med, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[4] Hamamatsu Univ Sch Med, Preeminent Med Photon Educ & Res Ctr, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
关键词
Thyroid cancer; Radioactive iodine therapy; Adjuvant therapy; Quantitative evaluation; Absolute radioactivity concentration; CARCINOMA; ABLATION;
D O I
10.1007/s12149-020-01546-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective Iodine-131 (I-131) radioactive iodine therapy (RAI) after total thyroidectomy is the standard treatment for patients with differentiated thyroid cancer (DTC). We investigated the relationship between the quantitative parameters of the iodine uptake and the disappearance of the accumulation in the thyroid bed in adjuvant therapy using a 1.11 GBq or 3.70 GBq dose of I-131. Methods We retrospectively analyzed the cases of 40 patients with DTC who were treated with RAI at our institution between April 2017 and August 2019. The patients were treated with the I-131 dose of 1.11 GBq (n = 25) or 3.70 GBq (n = 15) after total thyroidectomy. The I-131 whole-body scan and hybrid single-photon emission computed tomography/X-ray computed tomography (SPECT/CT) were performed 3 days after RAI. Using image analysis software, we measured the standardized uptake value (SUV) and absolute radioactivity concentration (kBq/ml) on the target lesions with the highest uptake in the thyroid bed. Results The median period from RAI to the evaluation of the absence of uptake of the thyroid bed was 6.75 months. After RAI, uptake of the thyroid bed disappeared in 26 of the 40 patients. The disappearance rate was significantly higher in the 3.70 GBq group than in the 1.11 GBq group (86.7% vs. 52.0%, respectively; p = 0.029). However, there were no significant differences in the values of kBq/ml or SUV between the 1.11 GBq group and 3.70 GBq group. On the other hand, the group in which the uptake disappeared after RAI showed significantly higher kBq/ml max and kBq/ml mean values than the group in which the uptake did not disappear after RAI (p = 0.028, p = 0.032, respectively). The SUVmax and SUVmean also tended to be higher in the disappeared-uptake group than the not-disappeared-uptake group, but the differences were not significant (p = 0.166, p = 0.176, respectively). Conclusions The quantitative evaluation might be useful as one of the predictive indicators of the disappearance of the accumulation of radioactive iodine in the thyroid bed.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 50 条
  • [1] The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer
    Kenta Konishi
    Ryo Ishiba
    Tsutomu Ikenohira
    Tomoyuki Asao
    Masanori Hirata
    Keiichi Ohira
    Tetsuya Komatsu
    Michifumi Sawada
    Yukichi Tanahashi
    Satoshi Goshima
    Yasuhiro Magata
    Katsumasa Nakamura
    Annals of Nuclear Medicine, 2021, 35 : 159 - 166
  • [2] Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer
    Bohinc, Brittany N.
    Perkins, Jennifer M.
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (01) : 31 - 35
  • [3] Radioactive iodine therapy in poorly differentiated thyroid cancer
    Tuttle, R. Michael
    Grewal, Ravinder K.
    Larson, Steve M.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (11): : 665 - 668
  • [4] Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update
    Ciarallo, Anthony
    Rivera, Juan
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2020, 215 (02) : 285 - 291
  • [5] Comparing therapeutic outcomes: radioactive iodine therapy versus non-radioactive iodine therapy in differentiated thyroid cancer
    Tiuca, Robert Aurelian
    Tiuca, Oana Mirela
    Pop, Raluca Monica
    Pascanu, Ionela Maria
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [6] Correlation analysis between the quantitative parameters of iodine-131 single-photon emission computed tomography-computed tomography thyroid bed uptake and the efficacy of radioactive iodine adjuvant therapy for papillary thyroid cancer
    Mao, Yangting
    Lin, Runlong
    Wang, Yizhen
    Yu, Jing
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2024, 14 (05) : 3665 - 3675
  • [7] Adjuvant Radioactive Iodine Use Among Differentiated Thyroid Cancer Patients in the Military Health System
    Gill, Abegail A.
    Enewold, Lindsey
    Zahm, Shelia H.
    Shriver, Craig D.
    Zheng, Li
    McGlynn, Katherine A.
    Zhu, Kangmin
    MILITARY MEDICINE, 2014, 179 (09) : 1043 - 1050
  • [8] Postoperative radioactive iodine administration for differentiated thyroid cancer patients
    Lepoutre-Lussey, Charlotte
    Deandreis, Desiree
    Leboulleux, Sophie
    Schlumberger, Martin
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2014, 21 (05) : 363 - 371
  • [9] Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers
    Toro-Tobon, David
    Morris, John C.
    Hilger, Crystal
    Peskey, Candy
    Durski, Jolanta M.
    Ryder, Mabel
    THYROID, 2024, 34 (01) : 70 - 81
  • [10] Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer
    Momesso, D. P.
    Vaisman, F.
    Caminha, L. S. C.
    Pessoa, C. H. C. N.
    Corbo, R.
    Vaisman, M.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2014, 37 (01) : 57 - 64